ClinicalTrials.gg
TerminatedNCT03713684AMPLITUDE-LUpdated Dec 2, 2021Results posted

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

A Phase 3 interventional study of Efpeglenatide SAR439977 and Placebo in Type 2 Diabetes Mellitus, sponsored by Sanofi. Terminated at 47 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-02.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision to cancel TRIAL, not related to safety concern

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
370
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.

Enrollment
79th of 178
370 · median 334
Started
2018
with 11 others
Phase 3
80 of 186
none open now
Registered
165th of 186
by date

Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 79th largest by enrollment of the 178 interventional ones that give a count, is one of 12 that started in 2018, is one of 80 in phase 3, and was the 165th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Diabetes Mellitus, Type 2 by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately controlled with basal insulin alone or in combination with oral antidiabetic drugs (OADs).

Secondary Objectives:

  • To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on glycemic control.
  • To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo on body weight.
  • To evaluate the safety of once weekly injection of efpeglenatide.
Read the detailed description

Study duration per participant was approximately 64 weeks including an up to 2-week Screening Period, a 30-week Core Treatment Period, a 26-week Safety Extension Period, and a 6-week safety Follow-up Period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be greater than or equal to (>=)18 years of age at the time of signing the .
  • Participants with T2DM.
  • Diabetes diagnosed at least 1 year before screening.
  • Participants on basal insulin regimen alone or in combination with OADs for at least 6 months prior to screening.
  • between 7.0 percent (%) and 10.0% (inclusive) measured by the central laboratory at screening.

Exclusion criteria

Exclusion criteria:

  • History of severe hypoglycemia requiring emergency room admission or hospitalization within 3 months prior to screening.
  • Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months prior to screening) or planned: intravitreal injections or laser or vitrectomy surgery.
  • history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to) gastroparesis, unstable and not controlled gastroesophageal reflux disease requiring medical treatment within 6 months prior to screening.
  • History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy.
  • Personal or family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).
  • Body weight change of >=5 kilograms within the last 3 months prior to screening.
  • Systolic blood pressure greater than (>)180 millimetres of mercury (mmHg) and/or diastolic blood pressure >100 mmHg at randomization.
  • End-stage renal disease as defined by estimated (by Modification of Diet in Renal Disease) of less than 15 mL/min/1.73 m\^2.
  • Laboratory findings at the screening Visit:

    • or aspartate aminotransferase >3 * (ULN) or total >1.5*ULN (except in case of documented Gilbert's syndrome);
    • Amylase and/or lipase: >3*ULN;
    • Calcitonin >=5.9 picomoles per liter (pmol/L) (20 picograms per milliliter [pg/mL]).
  • Gastric surgery or other gastric procedures intended for weight loss within 2 years prior to screening, or planned during study period.
  • Pregnant (confirmed by serum pregnancy test at screening) or breast-feeding women.
  • Women of not willing to use highly effective method(s) of or who were unwilling to be tested for pregnancy during the study period and for at least 5 weeks after the last dose of study intervention.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
370 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo (matched to efpeglenatide) subcutaneous (SC) injection once weekly up to Week 56 on top of basal insulin alone or in combination with oral antidiabetic drugs (OADs).

    Drug: Placebo · Drug: Background therapy

  • Experimental
    Efpeglenatide 2 mg

    Participants received Efpeglenatide 2 milligrams (mg) SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs.

    Drug: Efpeglenatide SAR439977 · Drug: Background therapy

  • Experimental
    Efpeglenatide 4 mg

    Participants received Efpeglenatide 4 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg and maintained at the 4 mg dose through-out the treatment duration up to Week 56.

    Drug: Efpeglenatide SAR439977 · Drug: Background therapy

  • Experimental
    Efpeglenatide 6 mg

    Participants received Efpeglenatide 6 mg SC injection once weekly up to Week 56 on top of basal insulin alone or in combination with OADs. Participants initiated dosing at 2 mg once weekly up to Week 1; which was up titrated to 4 mg until Week 4 and later up-titrated to 6 mg and maintained at the 6 mg dose through-out the treatment duration up to Week 56.

    Drug: Efpeglenatide SAR439977 · Drug: Background therapy

Interventions

  • Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • DrugPlacebo

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

  • DrugBackground therapy

    Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 30 in HbA1c

    Time frame: Baseline to Week 30

Secondary outcomes

  1. Number of Participants With HbA1c <7.0% at Week 30

    Participants who had no available assessment for HbA1c at Week 30 were considered as non-responders.

    Time frame: Week 30

  2. Change From Baseline to Week 56 in HbA1c

    This analysis included Week 56 assessment performed per protocol as well as premature end of treatment/study visit recorded as Week 56 due to early termination.

    Time frame: Baseline to Week 56

  3. Change From Baseline to Week 30 in Fasting Plasma Glucose (FPG)

    Time frame: Baseline to Week 30

  4. Change From Baseline to Week 30 and Week 56 in Body Weight

    This analysis included Week 56 assessment performed per protocol as well as premature end of treatment/study visit recorded as Week 56 due to early termination.

    Time frame: Baseline to Week 30 and Week 56

  5. Number of Participants With At Least One Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL], and Severe Hypoglycemia)

    Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

    Time frame: Baseline up to Week 56

  6. Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year

    Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

    Time frame: Baseline up to Week 56

07

Results

Posted Dec 2, 2021
Limitations and caveats
The study was terminated early by the Sponsor on 09 September 2020. Due to early termination of the study, few efficacy evaluations originally planned in the protocol were no longer considered to be relevant and were not performed. Primary, and secondary efficacy data were descriptively summarized and data were carefully considered given that the study was terminated early.

Participant flow

The study was conducted at 47 active sites in 3 countries. A total of 540 participants were screened between 09 November 2018 and 02 September 2020, out of which 170 were screen failures. Screen failures were mainly due to inclusion criteria not met.

Participant flow — Overall Study
MilestonePlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Started92929393
Safety population92929690
Completed 30-week core treatment period50525149
Completed6556
Not completed86878887
Withdrew: Adverse event1310
Withdrew: Poor compliance to protocol2101
Withdrew: Withdrawal by subject1461416
Withdrew: Other than specified69777370

Outcome measures

PrimaryChange From Baseline to Week 30 in HbA1c
Time frame:
Baseline to Week 30
Reported as:
Mean · percentage of HbA1c
Change From Baseline to Week 30 in HbA1c
percentage of HbA1cPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Change From Baseline to Week 30 in HbA1c-0.33 ± 1.09-1.27 ± 0.95-1.24 ± 0.96-1.43 ± 0.94
SecondaryNumber of Participants With HbA1c <7.0% at Week 30

Participants who had no available assessment for HbA1c at Week 30 were considered as non-responders.

Time frame:
Week 30
Reported as:
Count of participants · Participants
Number of Participants With HbA1c <7.0% at Week 30
ParticipantsPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Number of Participants With HbA1c <7.0% at Week 3010322840
SecondaryChange From Baseline to Week 56 in HbA1c

This analysis included Week 56 assessment performed per protocol as well as premature end of treatment/study visit recorded as Week 56 due to early termination.

Time frame:
Baseline to Week 56
Reported as:
Mean · percentage of HbA1c
Change From Baseline to Week 56 in HbA1c
percentage of HbA1cPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Change From Baseline to Week 56 in HbA1c-0.32 ± 0.86-1.08 ± 0.77-1.23 ± 0.88-1.16 ± 1.34
SecondaryChange From Baseline to Week 30 in Fasting Plasma Glucose (FPG)
Time frame:
Baseline to Week 30
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline to Week 30 in Fasting Plasma Glucose (FPG)
millimoles per liter (mmol/L)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Change From Baseline to Week 30 in Fasting Plasma Glucose (FPG)-0.41 ± 3.00-1.34 ± 2.80-1.33 ± 3.52-2.22 ± 1.89
SecondaryChange From Baseline to Week 30 and Week 56 in Body Weight

This analysis included Week 56 assessment performed per protocol as well as premature end of treatment/study visit recorded as Week 56 due to early termination.

Time frame:
Baseline to Week 30 and Week 56
Reported as:
Mean · kilograms
Change From Baseline to Week 30 and Week 56 in Body Weight
kilogramsPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Week 300.29 ± 3.23-0.68 ± 3.63-1.99 ± 3.13-3.14 ± 3.19
Week 560.66 ± 3.22-2.39 ± 10.69-1.77 ± 5.36-2.85 ± 4.80
SecondaryNumber of Participants With At Least One Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL], and Severe Hypoglycemia)

Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

Time frame:
Baseline up to Week 56
Reported as:
Count of participants · Participants
Number of Participants With At Least One Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL], and Severe Hypoglycemia)
ParticipantsPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Documented symptomatic hypoglycemia (<54 mg/dL)48109
Severe hypoglycemia1212
SecondaryNumber of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year

Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<54 mg/dL (\<3.0 mmol/L). Severe hypoglycemia was an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.

Time frame:
Baseline up to Week 56
Reported as:
Number · events per participant-year
Number of Hypoglycemic Events (Documented Symptomatic Hypoglycemia <3.0 mmol/L [<54 mg/dL] and Severe Hypoglycemia) Per Participant-Year
events per participant-yearPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
Documented symptomatic hypoglycemia (<54 mg/dL)0.070.270.450.46
Severe hypoglycemia0.090.050.050.04

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent up to end of study (up to Week 62). Time frame for reporting of treatment emergent adverse events (TEAEs) was from first injection of Investigational Medicinal Product (IMP) up to 30 days after the last injection of the IMP (i.e. up to Week 60).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/92 (0%)9/92 (9.8%)25/92 (27.2%)
Efpeglenatide 2 mg0/92 (0%)7/92 (7.6%)33/92 (35.9%)
Efpeglenatide 4 mg0/96 (0%)5/96 (5.2%)42/96 (43.8%)
Efpeglenatide 6 mg0/90 (0%)10/90 (11.1%)46/90 (51.1%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
SepsisInfections and infestations0/920/920/962/90
Non-Cardiac Chest PainGeneral disorders0/921/920/962/90
Covid-19 PneumoniaInfections and infestations0/920/922/960/90
Squamous Cell Carcinoma Of LungNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/920/920/961/90
SchizophreniaPsychiatric disorders0/920/920/961/90
Hypoglycaemic UnconsciousnessNervous system disorders0/921/921/961/90
CataractEye disorders0/920/920/961/90
Atrial FibrillationCardiac disorders0/920/920/961/90
Coronary Artery DiseaseCardiac disorders0/920/920/961/90
Myocardial InfarctionCardiac disorders0/921/920/961/90
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mg
NauseaGastrointestinal disorders6/9214/9219/9616/90
DiarrhoeaGastrointestinal disorders7/9210/9215/9614/90
ConstipationGastrointestinal disorders3/925/925/9614/90
Decreased AppetiteMetabolism and nutrition disorders1/922/9211/9613/90
VomitingGastrointestinal disorders4/924/9212/969/90
Gastrooesophageal Reflux DiseaseGastrointestinal disorders1/923/923/969/90
Lipase IncreasedInvestigations2/929/924/968/90
Amylase IncreasedInvestigations0/926/920/962/90
Abdominal PainGastrointestinal disorders1/924/926/963/90
Upper Respiratory Tract InfectionInfections and infestations5/924/924/965/90

Baseline characteristics

Analysis was performed on Intent-to-treat (ITT) population which included all participants randomized irrespective of compliance with the study protocol and procedures analyzed, according to the treatment group allocated by randomization.

Age, Continuous
Age, Continuous(years)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
Mean58.9 ± 10.759.1 ± 10.760.6 ± 11.561.6 ± 10.360.1 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
Female49424240173
Male43505153197
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
White45495150195
Black or African American9910836
Asian36333034133
Other21115
Unknown00101
Baseline Glycated Hemoglobin (HbA1c %)
Baseline Glycated Hemoglobin (HbA1c %)(percentage of HbA1c)PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
Mean8.54 ± 0.838.42 ± 0.798.46 ± 0.798.40 ± 0.728.46 ± 0.78
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))PlaceboEfpeglenatide 2 mgEfpeglenatide 4 mgEfpeglenatide 6 mgTotal
Mean30.1 ± 5.631.1 ± 6.130.0 ± 6.631.0 ± 7.130.6 ± 6.4
08

Study locations

47 sites
  • Investigational Site Number 8400038
    Birmingham, Alabama 35211, United States
  • Investigational Site Number 8400035
    Chandler, Arizona 85224, United States
  • Investigational Site Number 8400005
    Glendale, Arizona 85306, United States
  • Investigational Site Number 8400057
    Huntington Park, California 90255, United States
  • Investigational Site Number 8400058
    La Jolla, California 92037, United States
  • Investigational Site Number 8400009
    Los Angeles, California 90057, United States
  • Investigational Site Number 8400045
    Spring Valley, California 91978, United States
  • Investigational Site Number 8400040
    Tustin, California 92780, United States
  • Investigational Site Number 8400026
    Van Nuys, California 91405, United States
  • Investigational Site Number 8400055
    Orlando, Florida 32825, United States
  • Investigational Site Number 8400041
    Pembroke Pines, Florida 33026, United States
  • Investigational Site Number 8400025
    Lawrenceville, Georgia 30044, United States
  • Investigational Site Number 8400052
    West Des Moines, Iowa 50265, United States
  • Investigational Site Number 8400044
    Lexington, Kentucky 40503, United States
  • Investigational Site Number 8400001
    Bridgeton, New Jersey 08302, United States
  • Investigational Site Number 8400039
    New Windsor, New York 12553, United States
  • Investigational Site Number 8400036
    Morehead City, North Carolina 28557, United States
  • Investigational Site Number 8400013
    Maumee, Ohio 43537, United States
  • Investigational Site Number 8400030
    Dallas, Texas 75230, United States
  • Investigational Site Number 8400063
    Dallas, Texas 75390-9302, United States
  • Investigational Site Number 8400043
    San Antonio, Texas 78229, United States
  • Investigational Site Number 8400037
    Layton, Utah 84041, United States
  • Investigational Site Number 1560005
    Baotou, 014010, China
  • Investigational Site Number 1560017
    Beijing, 100730, China
  • Investigational Site Number 1560006
    Changsha, 410013, China
  • Investigational Site Number 1560001
    Chengdu, 610083, China
  • Investigational Site Number 1560004
    Shanghai, 014010, China
  • Investigational Site Number 1560036
    Shanghai, 200032, China
  • Investigational Site Number 1560012
    Shanghai, 200040, China
  • Investigational Site Number 1560013
    Shanghai, 200040, China
  • Investigational Site Number 1560003
    Zhengzhou, 450003, China
  • Investigational Site Number 4100009
    Busan, 49241, Korea, Republic of
  • Investigational Site Number 4100001
    Daejeon, 35233, Korea, Republic of
  • Investigational Site Number 4100016
    Gwangju, 501757, Korea, Republic of
  • Investigational Site Number 4100010
    Gwangju, 61453, Korea, Republic of
  • Investigational Site Number 4100013
    Gyeonggi-do, 11765, Korea, Republic of
  • Investigational Site Number 4100015
    Incheon, 21565, Korea, Republic of
  • Investigational Site Number 4100014
    Jeonju, 54907, Korea, Republic of
  • Investigational Site Number 4100007
    Seongnam-Si, 13620, Korea, Republic of
  • Investigational Site Number 4100008
    Seoul, 02447, Korea, Republic of
  • Investigational Site Number 4100002
    Seoul, 03080, Korea, Republic of
  • Investigational Site Number 4100005
    Seoul, 03722, Korea, Republic of
  • Investigational Site Number 4100004
    Seoul, 05278, Korea, Republic of
  • Investigational Site Number 4100003
    Seoul, 06351, Korea, Republic of
  • Investigational Site Number 4100011
    Seoul, 07345, Korea, Republic of
  • Investigational Site Number 4100006
    Seoul, 14647, Korea, Republic of
  • Investigational Site Number 4100012
    Suwon, 16247, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No plan to share individual participant data (IPD) by SANOFI: Product rights transferred to Hanmi Pharmaceutical.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Nov 2020, 24 months.

Results were first posted in Dec 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2018
First posted
Oct 22, 2018
StartActual
Nov 9, 2018
Primary completionActual
Nov 20, 2020
CompletionActual
Jan 4, 2021
Results first posted
Dec 2, 2021
Last update
Dec 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03713684
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 22, 2018
Start date
Nov 9, 2018
Primary completion
Nov 20, 2020
Completion
Jan 4, 2021
Results posted
Dec 2, 2021
Last update
Dec 2, 2021

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efpeglenatide

Start the discussion